The pathological and therapeutic roles of mesenchymal stem cells in preeclampsia

Sanshan Jin; Canrong Wu; Ming Chen; Dongyan Sun; Hua Zhang

doi:10.3389/fmed.2022.923334

The pathological and therapeutic roles of mesenchymal stem cells in preeclampsia

Front Med (Lausanne). 2022 Jul 28:9:923334. doi: 10.3389/fmed.2022.923334. eCollection 2022.

Authors

Sanshan Jin^{1

2}, Canrong Wu³, Ming Chen⁴, Dongyan Sun⁵, Hua Zhang^{1

2}

Affiliations

¹ Hubei University of Chinese Medicine, Wuhan, China.
² Department of Traditional Chinese Medicine, Maternal and Child Health Hospital of Hubei Province, Wuhan, China.
³ The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
⁴ Department of Rehabilitation Physiotherapy, Maternal and Child Health Hospital of Hubei Province, Wuhan, China.
⁵ Department of Gynecology, Maternal and Child Health Hospital of Hubei Province, Wuhan, China.

Abstract

Mesenchymal stem cells (MSCs) have made progress in the treatment of ischemic and inflammatory diseases. Preeclampsia (PE) is characterized by placenta ischemic and inflammatory injury. Our paper summarized the new role of MSCs in PE pathology and its potency in PE therapy and analyzed its current limitations. Intravenously administered MSCs dominantly distributed in perinatal tissues. There may be additional advantages to using MSCs-based therapies for reproductive disorders. It will provide new ideas for future research in this field.

Keywords: MSCs; MSCs transplantation; PE; exosome; placenta; pregnancy.

Publication types

Review